Ms. Will joins PharPoint as the company continues to grow and engage an increasing number of biotech and pharmaceutical clients seeking personalized attention, therapeutically aligned expertise, industry-best timelines, and decentralized study options.
As the situation with COVID-19 evolves, the PharPoint Research team is taking necessary precautions to ensure study operations continue uninterrupted. During this critical time in our industry, PharPoint remains fully dedicated, as always, to helping clients improve global health.
Last October, Turn Therapeutics was featured on Worldwide Business with kathy ireland®, where Turn founder and CEO Bradley Burnam shared his unique story of what makes Turn Therapeutics product different. PharPoint Research is proud to have worked with the Turn Therapeutics team as they continue to improve the lives and treatment options for patients of infectious disease.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.